DK2229391T3 - Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse - Google Patents
Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelseInfo
- Publication number
- DK2229391T3 DK2229391T3 DK08862089.3T DK08862089T DK2229391T3 DK 2229391 T3 DK2229391 T3 DK 2229391T3 DK 08862089 T DK08862089 T DK 08862089T DK 2229391 T3 DK2229391 T3 DK 2229391T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrido
- pyrazine
- substituted compounds
- substituted
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1501907P | 2007-12-19 | 2007-12-19 | |
PCT/GB2008/004208 WO2009077766A1 (en) | 2007-12-19 | 2008-12-19 | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2229391T3 true DK2229391T3 (da) | 2014-10-13 |
Family
ID=40342728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08862089.3T DK2229391T3 (da) | 2007-12-19 | 2008-12-19 | Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse |
Country Status (19)
Country | Link |
---|---|
US (5) | US8198279B2 (da) |
EP (1) | EP2229391B1 (da) |
JP (1) | JP5511680B2 (da) |
KR (1) | KR101665143B1 (da) |
CN (1) | CN101945869B (da) |
AU (1) | AU2008337286B2 (da) |
BR (1) | BRPI0821227A2 (da) |
CA (1) | CA2709257C (da) |
DK (1) | DK2229391T3 (da) |
EA (1) | EA019974B1 (da) |
ES (1) | ES2520940T3 (da) |
HK (1) | HK1148521A1 (da) |
IL (1) | IL206330A (da) |
MX (1) | MX2010006739A (da) |
NZ (1) | NZ586418A (da) |
PL (1) | PL2229391T3 (da) |
UA (1) | UA105763C2 (da) |
WO (1) | WO2009077766A1 (da) |
ZA (1) | ZA201004524B (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
BR112012018415A2 (pt) | 2010-02-01 | 2020-08-04 | Cancer Research Technology Limited | composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto. |
WO2011124930A1 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | P38 map kinase inhibitors |
WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
DK2614369T3 (da) | 2010-09-10 | 2016-05-02 | Epizyme Inc | Fremgangsmåde til bestemmelse af egnetheden for inhibitorer af human ezh2 i behandling |
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
EP2747767B8 (en) | 2011-08-26 | 2019-07-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
AU2012308238B2 (en) | 2011-09-14 | 2017-05-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN103130686B (zh) * | 2011-12-02 | 2016-09-14 | 天津市国际生物医药联合研究院 | N,n′-不对称二芳基取代脲类化合物及其制备方法和用途 |
US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
PT3628670T (pt) | 2012-04-13 | 2022-12-02 | Epizyme Inc | Forma salina de um inibidor de ezh2 |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
NZ746490A (en) | 2012-10-02 | 2018-12-21 | Bayer Cropscience Ag | Heterocyclic compounds as pesticides |
RU2658919C2 (ru) | 2012-10-15 | 2018-06-26 | Эпизайм, Инк. | Замещенные бензольные соединения |
EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
PT3057962T (pt) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Forma de sal cloridrato para inibição de ezh2 |
GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
CA3015455A1 (en) | 2016-02-23 | 2017-08-31 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
EP3709991A1 (en) | 2017-11-13 | 2020-09-23 | Greg Hannon | Dietary product |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
GB201818649D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
GB201818651D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
US20230089368A1 (en) * | 2019-07-19 | 2023-03-23 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
KR20220066258A (ko) | 2019-08-08 | 2022-05-24 | 비.씨.아이. 파르마 | 단백질 키나아제 억제제로서의 퀴놀린 유도체 |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
WO2021262915A1 (en) * | 2020-06-24 | 2021-12-30 | Purdue Research Foundation | 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors |
CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
CN114105876A (zh) * | 2021-12-08 | 2022-03-01 | 沈阳科创化学品有限公司 | 一种制备乙唑螨腈中间体的方法 |
GB202208347D0 (en) | 2022-06-07 | 2022-07-20 | Univ Court Univ Of Glasgow | Targets for cancer therapy |
GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
CN115884487B (zh) * | 2023-02-16 | 2023-05-26 | 浙大城市学院 | 基于针式协同双螺旋电极介质阻挡放电管 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082845A (en) | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
US4666828A (en) * | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) * | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) * | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5879672A (en) * | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
US5643755A (en) * | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
JPH10506011A (ja) * | 1994-09-22 | 1998-06-16 | ヘルシンキ、ユニバーシティ、ライセンシング、リミテッド、オサケ、ユキチュア | レセプターチロシンキナーゼ、tieのプロモーター |
EP0951541B1 (en) * | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) * | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
DE69622183D1 (de) * | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
NZ503432A (en) | 1997-09-26 | 2002-11-26 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
WO1999032436A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
US20010053946A1 (en) * | 1998-09-04 | 2001-12-20 | R. R. Donnelley & Sons Company | System for controlling feeders of a package assembly apparatus |
HUP0104693A3 (en) | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
US6696440B1 (en) | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
DE60033857T2 (de) * | 1999-01-22 | 2007-10-25 | Kirin Beer K.K. | Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität |
WO2000045435A1 (en) | 1999-01-29 | 2000-08-03 | The University Of Akron | Polyimides used as microelectronic coatings |
NZ515567A (en) | 1999-07-16 | 2004-03-26 | Warner Lambert Co | Method for treating chronic pain using MEK inhibitors |
RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
ES2245955T3 (es) | 1999-12-21 | 2006-02-01 | Sugen, Inc. | 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa. |
US6492529B1 (en) * | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
US7238813B2 (en) * | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
KR20020096367A (ko) | 2001-06-19 | 2002-12-31 | 주식회사 티지 바이오텍 | 관절염 예방 또는 치료제 및 그것의 스크리닝 방법 |
NZ532780A (en) | 2001-12-21 | 2006-10-27 | Wellcome Trust | Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them |
US20030180226A1 (en) | 2002-01-23 | 2003-09-25 | Haughton Pauline A. | Anti-bacterial sneeze spray |
CA2493575A1 (en) | 2002-08-09 | 2004-02-19 | Christopher J. Dinsmore | Tyrosine kinase inhibitors |
WO2004083458A1 (en) | 2003-03-20 | 2004-09-30 | Universite Catholique De Louvain | Medical use of ras antagonists for the treatment of capillary malformation |
CN1805748B (zh) | 2003-06-13 | 2010-05-26 | 诺瓦提斯公司 | 作为raf激酶抑制剂的2-氨基嘧啶衍生物 |
BRPI0507609A (pt) | 2004-02-13 | 2007-07-03 | Pfizer Prod Inc | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina |
TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
WO2006024834A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
WO2006040568A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
EP1835934A4 (en) | 2004-12-23 | 2010-07-28 | Deciphera Pharmaceuticals Llc | ENZYME MODULATORS AND TREATMENTS |
CA2629468A1 (en) | 2005-11-15 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Pyrazolyl urea derivatives useful in the treatment of cancer |
US20110195110A1 (en) | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
ZA200804679B (en) | 2005-12-08 | 2010-02-24 | Millenium Pharmaceuticals Inc | Bicyclic compounds with kinase inhibitory activity |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
CN101040720A (zh) | 2006-03-24 | 2007-09-26 | 沈华立 | 一种豆腐干的五香麻辣卤汤液 |
JP2009534364A (ja) * | 2006-04-18 | 2009-09-24 | アストラゼネカ アクチボラグ | キナゾリン−4−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物 |
AU2007245495A1 (en) | 2006-04-26 | 2007-11-08 | Astex Therapeutics Limited | Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
WO2008044688A1 (fr) | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Dérivé de l'urée |
CN103933572B (zh) | 2006-11-20 | 2017-10-13 | 哈佛大学校长及研究员协会 | 治疗疼痛和瘙痒的方法、组合物和试剂盒 |
JP2010532989A (ja) | 2007-07-10 | 2010-10-21 | ニューリム ファーマシューティカルズ (1991) リミテッド | 神経変性疾患におけるcd44スプライスバリアント |
CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2288922B1 (en) | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
US8293748B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
AU2009326148B2 (en) | 2008-12-11 | 2014-05-08 | Respivert Limited | p38 MAP kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
WO2011028540A1 (en) | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
BR112012018415A2 (pt) | 2010-02-01 | 2020-08-04 | Cancer Research Technology Limited | composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto. |
GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
WO2011124930A1 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | P38 map kinase inhibitors |
GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
WO2012008564A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
WO2012149547A1 (en) | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
US8883797B2 (en) | 2011-06-23 | 2014-11-11 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
CA2845571A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Use of organic compound for the treatment of noonan syndrome |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
ES2583853T3 (es) | 2011-10-03 | 2016-09-22 | Respivert Limited | 1-Pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de p38 MAP cinasa |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
CN105408315B (zh) | 2013-04-02 | 2018-09-14 | 瑞斯比维特有限公司 | 激酶抑制剂 |
US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
ES2677595T3 (es) | 2014-02-14 | 2018-08-03 | Respivert Limited | Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios |
US20170209445A1 (en) | 2014-10-01 | 2017-07-27 | Respivert Limited | Kinase inhibitors |
MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
-
2008
- 2008-12-19 CA CA2709257A patent/CA2709257C/en not_active Expired - Fee Related
- 2008-12-19 KR KR1020107015083A patent/KR101665143B1/ko active IP Right Grant
- 2008-12-19 CN CN200880126717.3A patent/CN101945869B/zh not_active Expired - Fee Related
- 2008-12-19 US US12/808,249 patent/US8198279B2/en active Active
- 2008-12-19 BR BRPI0821227-9A patent/BRPI0821227A2/pt not_active Application Discontinuation
- 2008-12-19 EP EP08862089.3A patent/EP2229391B1/en active Active
- 2008-12-19 UA UAA201008265A patent/UA105763C2/uk unknown
- 2008-12-19 NZ NZ586418A patent/NZ586418A/xx unknown
- 2008-12-19 PL PL08862089T patent/PL2229391T3/pl unknown
- 2008-12-19 AU AU2008337286A patent/AU2008337286B2/en not_active Ceased
- 2008-12-19 WO PCT/GB2008/004208 patent/WO2009077766A1/en active Application Filing
- 2008-12-19 JP JP2010538900A patent/JP5511680B2/ja active Active
- 2008-12-19 MX MX2010006739A patent/MX2010006739A/es active IP Right Grant
- 2008-12-19 ES ES08862089.3T patent/ES2520940T3/es active Active
- 2008-12-19 EA EA201070667A patent/EA019974B1/ru not_active IP Right Cessation
- 2008-12-19 DK DK08862089.3T patent/DK2229391T3/da active
-
2010
- 2010-06-13 IL IL206330A patent/IL206330A/en active IP Right Grant
- 2010-06-25 ZA ZA2010/04524A patent/ZA201004524B/en unknown
-
2011
- 2011-03-15 HK HK11102596.1A patent/HK1148521A1/xx not_active IP Right Cessation
-
2012
- 2012-04-28 US US13/459,120 patent/US8546387B2/en not_active Expired - Fee Related
-
2013
- 2013-09-24 US US14/035,133 patent/US8912191B2/en not_active Expired - Fee Related
-
2014
- 2014-11-17 US US14/543,379 patent/US9155737B2/en not_active Expired - Fee Related
-
2015
- 2015-09-14 US US14/853,199 patent/US9540372B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2229391T3 (da) | Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse | |
BRPI0919948A2 (pt) | Pirido[4,3-b]indois contendo porções rígidas | |
DOP2007000080A (es) | Piridin [3,4-b] pirazinonas | |
ATE415400T1 (de) | Pyrazolopyridinderivate | |
ZA200906736B (en) | New 3-([1,2,4] Triazolo [4,3-A]Pyridin-7-YL) Benzamide derivatives | |
EP1863809A4 (en) | PYRAZOLOPYRIDINES AND THE LIKE | |
SI2069342T1 (sl) | Derivati aril fenil imidazo a piridinov njihova priprava in njihova terapevtska uporaba | |
IL198250A0 (en) | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b | |
BRPI0822237A2 (pt) | Compostos de imidazo [1,2-a] piridina | |
BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
EP2124550A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE | |
IL204663A0 (en) | Nicotinamide derivatives, preparastion thereof and therapeutic use thereof | |
BRPI0908050A2 (pt) | Furo-e tieno[3,2-c]piridinas | |
SMP200800029B (it) | 2-ammino-7,8-diidro-6h-pirido[4,3-d]pirimidin-5-oni | |
BRPI1014459A2 (pt) | derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina" | |
GB0702259D0 (en) | 7-azaindole derivatives | |
EP1988090A4 (en) | IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, METHOD OF MANUFACTURE AND USE THEREOF | |
DE602008005634D1 (de) | 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate | |
DK2124944T3 (da) | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer | |
DE102008005493A8 (de) | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate | |
IL202139A0 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
EP2077028A4 (en) | WITH NAME INQUIRY ACTIVATED ZONES | |
HK1122797A1 (en) | Derivatives of pyrido | |
EP1961753A4 (en) | DERIVATIVES OF PIRAZOLOPYRIMIDINONE, THEIR PREPARATION AND USE | |
IL182739A0 (en) | Acylatednonadepsipeptides used as lysobactin derivatives |